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Background: Cigarette smoking is the most important risk factor for Chronic Obstructive Pulmonary Disease
(COPD). Only a subgroup of smokers develops COPD and it is unclear why these individuals are more susceptible to
the detrimental effects of cigarette smoking. The risk to develop COPD is known to be higher in individuals with
familial aggregation of COPD. This study aimed to investigate if acute systemic and local immune responses to
cigarette smoke differentiate between individuals susceptible or non-susceptible to develop COPD, both at young
(18-40 years) and old (40-75 years) age.
Methods: All participants smoked three cigarettes in one hour. Changes in inflammatory markers in peripheral
blood (at 0 and 3 hours) and in bronchial biopsies (at 0 and 24 hours) were investigated. Acute effects of smoking
were analyzed within and between susceptible and non-susceptible individuals, and by multiple regression analysis.
Results: Young susceptible individuals showed significantly higher increases in the expression of FcγRII (CD32) in its
active forms (A17 and A27) on neutrophils after smoking (p = 0.016 and 0.028 respectively), independently of age,
smoking status and expression of the respective markers at baseline. Smoking had no significant effect on
mediators in blood or inflammatory cell counts in bronchial biopsies. In the old group, acute effects of smoking
were comparable between healthy controls and COPD patients.
Conclusions: We show for the first time that COPD susceptibility at young age associates with an increased
systemic innate immune response to cigarette smoking. This suggests a role of systemic inflammation in the early
induction phase of COPD.
Trial registration: Clinicaltrials.gov: NCT00807469
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Cigarette smoking is the most important risk factor for
Chronic Obstructive Pulmonary Disease (COPD) [1].
However, only a proportion of all smokers, about 15-20%,
will actually develop COPD, the so-called ‘susceptible’
smokers. It is still unclear which factors determine why
these individuals are more sensitive to the detrimental* Correspondence: n.h.t.ten.hacken@umcg.nl
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article, unless otherwise stated.effects of cigarette smoking compared with ‘non-suscep-
tible’ smokers.
To better understand how cigarette smoking leads to ir-
reversible lung damage and chronic airflow obstruction,
knowledge of the initial responses to cigarette smoking
might be very useful. Several studies investigated the acute
inflammatory and oxidative stress responses to cigarette
smoking in animal and in vitro models, yet only a few
studies investigated these responses in humans [2]. These
studies focused generally on COPD patients and ‘healthy
smokers’ without airway obstruction. However, aging and
the cumulative amount of pack-years smoking may lead
to changes in the airways and lung parenchyma in bothtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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ing. Particularly in COPD, the structural changes in the
lung may lead to a different response to smoking. For
this reason, it might be hypothesized that the very first
responses to cigarette smoking in healthy young individ-
uals with a low number of pack-years is an ideal model
to investigate the induction and early progression to-
wards COPD.
Several family studies have provided evidence that
a genetic predisposition is involved in the smoking-
related development of COPD. Silverman et al. showed
that smoking or ex-smoking in first degree relatives of
early-onset COPD probands associates significantly
with lower forced expiratory volume in one second
(FEV1) values compared to relatives of control subjects
[3]. Several other studies have demonstrated that the
combination of smoking and familial clustering of
COPD strongly associates with a higher risk for COPD
[4-6]. Although a history of familial COPD may help to
identify smokers who are susceptible to develop COPD
themselves, a more discriminative biomarker would be
welcome in the field of preventive medicine. Additionally,
elucidating the smoking-induced pathogenesis of COPD
in susceptible individuals may ultimately lead to the iden-
tification of new drug targets.
The aim of this study was to identify early biomarkers
of COPD susceptibility by investigating acute responses
to cigarette smoke in young (18-40 years) individuals
susceptible and non-susceptible to develop COPD, based
on a high prevalence or absence of COPD in smoking
relatives. All subjects smoked three cigarettes in one hour.
Before and after smoking, inflammatory markers were
determined in peripheral blood and bronchial biopsies.
We hypothesized that susceptible individuals exhibit a
different systemic and local inflammatory response
compared to non-susceptible individuals. In addition,
we investigated the acute response to cigarette smok-
ing in older (ex) smokers with and without COPD, to
assess if responses to cigarette smoking change after
many years of smoking.Figure 1 Time frame of the acute smoking procedure. Definition of a
Exhaled CO was obtained at baseline, directly after smoking, and 2 hou
baseline and 2 hours after smoking the last cigarette. Bronchial biopsie
biopsies were obtained as baseline measurement. Subjects refrained fro
and the baseline bronchoscopy after 6 weeks. In addition, subjects refra
24 hrs bronchoscopy.Methods
Study population
Young individuals (age 18-40 years) who are susceptible
or non-susceptible to develop COPD were included [7].
All young subjects were intermittent smokers, able to
quit smoking for at least 2 days and start smoking on re-
quest. Furthermore, we included mild-to-moderate COPD
patients (FEV1 30-80% predicted, FEV1/FVC <0.7, >10
pack-years), and smokers without airway obstruction
(FEV1/FVC >0.7, >20 pack-years). Exclusion criteria are
mentioned in the online supplement (Additional file 1).
The study was performed at the University Medical
Center Groningen (UMCG) (NCT00807469, http://clinical-
trials.gov/show/NCT00807469). The medical ethics commit-
tee of the UMCG approved the study protocol and all
subjects gave written informed consent.
Study design
Baseline and follow-up measurements were performed
after smoking three cigarettes within one hour (Figure 1).
Subjects quitted smoking for at least two days prior
baseline visits, and refrained from smoking between the
acute smoking procedure and the 24-hrs bronchoscopy.
Refraining from smoking was verified by exhaled carbon
monoxide (CO) measurements being <5 parts per million
(ppm) and sufficient inhalation of the three cigarettes by a
rise in CO (Micro+ Smokerlyzer®, Bedfont Scientific Ltd,
Kent, England). Subjects were not allowed to participate
in the acute smoking procedure if their CO measurement
was >5 ppm at baseline.
Measurements
Demographic characteristics were obtained and spirometry,
body plethysmography and CO-diffusion were performed
according to standardized guidelines [8,9].
Before and after smoking, blood was collected in sodium
heparin tubes or serum tubes to perform flow cytometry
analysis (FACs) on neutrophil activation markers and
cytokine quantification respectively. Detailed methodsbbreviations: CO = carbon monoxide, min = minutes, h = hours.
rs after smoking the last cigarette. Blood samples were collected at
s were obtained 24 hours after smoking. Six weeks later bronchial
m smoking during two days before the baseline measurements
ined from smoking after the acute smoking procedure until the
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Briefly, leucocytes were triple stained with antibodies
against (FcγRII) CD32, Mac-1 (CD11b), ICAM-1 (CD54),
IL-8 receptors (CD181/CXCR1, CD182/CXCR2) com-
bined with antibodies directed against L-selectin (CD62L)
and FcγRIII (CD16). Additionally, the expression of the
active form of FcγRII (CD32) was identified by monoclo-
nal phages antibodies MoPhab A17 and A27 [10]. Cells
were analyzed in a flow cytometer (FACScalibur; BD
Biosciences). Within the granulocyte population (identi-
fied based on forward (FCS) and side-scatter (SSC)),
neutrophils were identified by CD16high expression and
eosinophils by CD16low expression. Flow cytometry data
was analysed by FCS Express Version 3 (De Novo soft-
ware) and median fluorescence intensities (MFI) were
calculated. Cytokine quantification was performed by
multiplex analyses (Milliplex, Millipore Corporation,
Billerica, MA, USA).
Bronchial biopsies were taken from subsegmental
carinae of the right or left lower lobe. Briefly, biopsies
were fixed in 4% neutral buffered formalin, processed
and embedded in paraffin and cut in 3 μm sections. Im-
munohistochemical stainings were performed using the
DAKO autostainer (DAKO, Glostrup, Denmark) using
antibodies against inflammatory cells. Detailed immu-
nohistochemistry and quantification procedures are pre-




Age, years 21 (20-23)
Gender, male n (%) 17 (59)
Pack-years 1 (0-3)
Current smokers, n (%) 29 (100)
Ex-smokers, n (%) 0 (0)
Non-smoker, n (%) 0 (0)
Cig./day for smoking subjects, n 3 (1-10)
FEV1, %predicted 106 (101-112)
FEV1/FVC, % 85 (83-91)
RV/TLC, % 22 (19-24)
TLCO/VA, %predicted 100 (92-110)
MEF50, %predicted 97 (85-119)
hsCRP, mg/L 0.7 (1.6-1.9)
Blood neutrophils, ×109/L 3.3 (2.7-3.9)
Blood eosinophils, ×109/L 0.16 (0.13-0.26)
Definition of abbreviations: n number, FEV1 Forced Expiratory Volume in one second
TLCO/VA transfer coefficient for carbon monoxide, MEF50 maximal expiratory flow a
Data are expressed as medians with interquartile ranges (IQR), unless stated otherw
<0.05, COPD versus healthy controls.Data analyses
Group characteristics were analyzed using Mann-Whitney
U tests or Chi-squared tests. The Wilcoxon signed-rank
test was performed to test acute smoking effects within
groups. Absolute changes with smoking were analyzed
between groups using Mann-Whitney U tests. Multiple
linear regression analysis was performed with absolute
change in the variables tested as dependent variable and
susceptibility to COPD (n/y) as predictor variable. Models
were adjusted for relevant co-variables. Data were normal-
ized by log-transformation if necessary. Linear regression
models were considered valid if the residuals were nor-
mally distributed. Statistical analyses were performed




Table 1 presents the clinical characteristics of subjects
that were included in the study: 50 young individuals, 29
non-susceptible and 21 susceptible, and 40 older sub-
jects, 27 healthy controls and 13 COPD patients. All
subjects successfully performed the acute smoking pro-
cedure. However, from the total group (n = 90) 6 sub-
jects had missing data in the flow cytometry analyses
due to technical reasons and 19 subjects (young non-
susceptible: n = 4, young susceptible: n = 7, healthy controls:Old (>40 years)
Susceptible Healthy controls COPD
(n = 21) (n = 27) (n = 13)
31 (22-38)* 51 (46-62) 66 (64-70)†
11 (52) 23 (85) 13 (100)
5 (2-10)* 26 (23-36) 32 (23-46)
13 (62)* 26 (96) 10 (77)
0 (0) 1 (4) 3 (23)
8 (38) 0 (0) 0 (0)
8 (2-17) 14 (8-20) 6 (3-14)†
110 (104-114) 106 (102-116) 65 (60-75)†
81 (78-87)* 78 (74-83) 50 (38-59)†
25 (23-28) 32 (28-37) 39 (34-48)†
95 (82-105) 100 (91-106) 75 (63-96)†
94 (85-108) 90 (80-151) 23 (12-29)†
1.0 (0.6-2.2) 1.9 (0.6-3.8) 2.9 (1.0-5.0)
3.8 (2.9-4.4) 3.5 (2.7-4.7) 3.8 (3.3-5.0)
0.12 (0.10-0.19) 0.17 (0.10-0.20) 0.20 (0.1-0.4)
, FVC Forced Vital Capacity, RV Residual Volume, TLC Total Lung Capacity,
t 50% of vital capacity, hsCRP high-sensitivity C-Reactive Protein.
ise. *p-value <0.05, young susceptible versus young non-susceptible. †p-value
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biopsy data because subjects did not want to undergo a
second bronchoscopy.
Exhaled CO
The baseline median (IQR) exhaled CO value was 1 (1-2)
in the whole group, and values were significantly increased
in all groups after smoking; 5 (3-10) in young non-
susceptible, 7 (4-11) in young susceptible, 8 (6-10) in
old healthy controls and 5 (3-8) in COPD patients respect-
ively. There were no significant differences between the
study groups in median exhaled CO levels after smoking.
Flow cytometry on systemic inflammatory cells
Table 2 presents changes in cell-surface marker expression
on neutrophils in the young groups with smoking. Absolute
values before and after smoking are presented in Additional
file 1: Table E1. In the susceptible group, CD32 and CD54
expression decreased, and expression of active FcγRII (clones
A17 and A27) increased significantly as demonstrated in
Figure 2. In the non-susceptible group CD181/CXCR1 ex-
pression was significantly decreased. Figures 2 and 3 show
that CD182/CXCR2 expression, and percentages of eo-
sinophils (CD16− granulocytes) and neutrophils (CD16+
granulocytes) similarly decreased in the two groups.
Differential responses to smoking were borderline sig-
nificant between groups as follows: CD54 decreased more
and A17 and A27 increased more in the young susceptible
group (Figure 2). CD181/CXCRI expression increased
more in the young non-susceptible group (Figure 2).
Finally, eosinophil percentages decreased more in the
non-susceptible group (Figure 3).
Cytokine concentrations in serum
Changes in cytokine levels with smoking are presented




CD16+ Neutrophils 3.4 (-1.3;6.7)*
CD16− Eosinophils −3.6 (-5.6;-2.4)*
CD11b (Mac-1) −4.6 (-20.3;18.6)
CD32 (FcγRII) −12.6 (-23.9;2.67)
CD54 (ICAM-1) −0.8 (-1.6;0.48)
CD181/CXCR1 (IL-8 receptor) −19.2 (-48.2;-2.6)*
CD182/CXCR2 (IL-8 receptor) −23.5 (-53.0;-6.5)*
A17 (active FcγRII) 3.26 (-3.0;3.3)
A27 (active FcγRII) 0.4 (-9.6;14.6)
Values are expressed as median change (Tafter-Tbefore) in fluorescence intensity (MFI
to cigarette smoke within the group (Wilcoxon signed-rank tests, p < 0.05). †p-value
non-susceptible subjects (Mann-Whitney U tests, NS = not significant).values before and after smoking). IL-8 and GM-CSF
were significantly decreased in the non-susceptible group,
whereas IL-7 significantly increased. Furthermore, TNFα
was significantly decreased in both groups. The changes
with smoking were not significantly different between the
susceptibility groups.Inflammatory cells in bronchial biopsies after smoking
Table 4 presents the changes in inflammatory cell
counts in bronchial biopsies 24 hours after smoking
(see Additional file 1: Table E1 for absolute values before
and after smoking). Eosinophils (EPX immunopositivity)
was significantly increased in the non-susceptible group.
The changes of bronchial cell counts were not signifi-
cantly different with smoking between groups.Susceptibility as predictor of systemic responses to
cigarette smoking
We assessed whether susceptibility predicted the changes
in expression of CD54, CD181/CXCR1, active FcγRII
(clones A17 and A27) and percentage of eosinophils with
smoking by multiple linear regression models. Table 5
shows that susceptibility was a significant predictor of the
change in A17 and A27 expression after smoking, inde-
pendently of expression at baseline, age and smoking
status. Susceptibility was not associated with CD54 and
CD181/CXCR1 expression, and percentage of eosinophils.
Additionally, using multiple linear regression analysis,
we investigated if the changes in expression of neutro-
phil activation markers were predictors of the change
in number of neutrophils in bronchial biopsies. Both a
higher increase in CD54 expression of blood neutrophils
and susceptibility were significant predictors of a
higher increase of bronchial neutrophils counts (Table 6,







−1.6 (-23.0;-0.13)* NS (0.072)
−5.2 (-27.9;9.8) NS (0.073)
−27.7 (-46.5;0.7)* NS
14.8 (2.6;71.0)* NS (0.067)
19.0 (0.8;67.8)* NS (0.078)
) with interquartile ranges (IQR), two hours after smoking. *Significant response
s for differences in responses to cigarette smoke between susceptible and
Figure 2 Effects of acute smoking on expression of neutrophil activation markers in young subjects. Values are expressed as median
fluorescence intensity (MFI) with range, before and two hours after smoking. The responses to cigarette smoke within groups were analyzed by
Wilcoxon signed-rank tests. Differences in responses to cigarette smoke between susceptible and non-susceptible groups were analyzed by
comparing delta’s (Tafter-Tbefore) using Whitney U tests. *p < 0.05, NS = not significant.
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without airway obstruction
Data of the acute smoking procedure in the old groups
are presented in Additional file 1: Table E2. Briefly, we
observed no significant differences in the change of neu-
trophil marker expression after smoking between COPD
patients and controls, whereas the decrease in the per-
centage of eosinophils was larger in COPD patients. IL-6
and IL-8 levels in blood decreased after smoking inhealthy controls, a change that was close to significance
when compared with the change in COPD patients. Finally,
the change in number of bronchial neutrophils significantly
differed between groups, showing an increase in healthy
controls and a decrease in COPD patients.
Discussion
This is the first human study using an acute smoking de-
sign in a population of young and old individuals being
Figure 3 Effects of acute smoking on total neutrophils and eosinophils in young subjects. Values are expressed as median percentage
with range, before and two hours after smoking. The responses to cigarette smoke within groups were analyzed by Wilcoxon signed-rank tests.
Differences in responses to cigarette smoke between susceptible and non-susceptible groups were analyzed by comparing delta’s (Tafter-Tbefore)
using Whitney U tests. *p < 0.05, NS = not significant.
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focus of this study was on the comparison of the acute
response to cigarette smoking in young individuals,
older subjects were investigated to assess if responses
change after many years of smoking. We demonstrated
that susceptibility to develop COPD at young age asso-
ciates with an enhanced innate immune response to
cigarette smoking in peripheral blood when compared
with non-susceptible individuals, suggesting that a sys-
temic inflammatory component is involved during the
induction of COPD.Table 3 Cytokines measured in blood 2 hours after
smoking
Change with smoking
Young non-susceptible Young susceptible p-value†
(n = 29) (n = 21)
IL−1β 0.00 (0.00;0.00) 0.00 (0.00;0.00) NS
IL−6 0.00 (−0.25;0.15) −0.04 (−1.0;0.06) NS
IL−8 −0.70 (−1.56;−0.01)* −0.24 (−1.03;0.68) NS
GM−CSF 0.00 (−0.20;0.00)* 0.00 (−0.54;0.00) NS
TNFα −0.27 (−0.89;0.00)* −0.35 (−1.11;0.16)* NS
IFNγ 0.00 (−0.84;1.10) −0.49 (−1.59;1.13) NS
IL-2 0.00 (−0.46;0.70) 0.00 (−0.70;0.48) NS
IL-4 0.00 (−0.91;0.00) 0.00 (−0.11;0.00) NS
IL-5 0.00 (−0.09;0.09) 0.00 (−0.05;0.00) NS
IL-7 0.79 (0.00;3.97)* 0.00 (−1.07;3.39) NS
IL-10 0.00 (−1.81;0.00) 0.00 (−1.35;1.46) NS
IL-12p70 0.00 (−0.31;0.24) 0.00 (−0.83;0.31) NS
IL-13 0.00 (0.00;1.65) 0.00 (−1.10;1.63) NS
Values are expressed as median change (Tafter-Tbefore) in cytokine
concentration (pg/ml) with interquartile ranges (IQR), two hours after smoking.
*Significant response to cigarette smoke within the group (Wilcoxon signed-rank
tests, p < 0.05). †p−values for differences in responses to cigarette smoke
between susceptible and non−susceptible subjects (Mann−Whitney U tests,
NS = not significant).Our most important finding is that peripheral blood
neutrophil activation markers were differentially expressed
after smoking between young susceptible and young non-
susceptible subjects. Previous human studies have shown
that the number of peripheral blood neutrophils increases
after acute smoking [2], a finding that we confirmed,
i.e. neutrophils (CD16+ granulocytes) significantly in-
creased in both the susceptible and non-susceptible group
(Figure 3). However, the activation of neutrophils is a
well-described multi-step process, generally starting with
priming (pre-activation) caused by chemotaxins or cyto-








(n = 25) (n = 14)
Submucosal
CD3+ T-cells 6.8 (−21.9;21.6) 3.2 (−9.1;15.3) NS
CD4+ T-cells 0.0 (−2.8;11.8) −0.4 (−7.4;1.5) NS
CD8+ T-cells 0.2 (−0.8;16.5) −8.9 (−29.9;11.3) NS
FOXP3+ T-cells 0.9 (−1.9;2.2) 0.2 (−0.3;1.8) NS
CD68+
macrophages
2.3 (−1.2;7.2) −0.4 (−4.0;2.6) NS
AA1+ mast cells 0.0 (−2.1;11.8) 1.1 (−3.5;2.7) NS
EPX+ eosinophils 0.8 (0.0;1.0)* 0.0 (−0.7;1.0) NS
NP57+ neutrophils 1.2 (−5.8;5.2) 1.7 (−6.8;7.4) NS
% E-selectin pos.
vessels
0.0 (−1.0;0.0) 0.0 (−5.2;0.0) NS
Values are expressed as median change (Tafter-Tbefore) in cell counts with
interquartile ranges (IQR), 24 hours after smoking. Inflammatory cells are
expressed as cell counts/0.1 mm2. *Significant response to cigarette smoke
within the group (Wilcoxon signed-rank tests, p < 0.05). †p-values for differences in
responses to cigarette smoke between susceptible and non-susceptible subjects
(Mann-Whitney U tests, NS = not significant).
Table 5 Associations of susceptibility (no/yes) with the
change in expression of neutrophil markers after
smoking
Dependent variable: change
in expression with smoking
Predictor variable: susceptibility y/n†
n = 47 B S.E. p-value
(CD181/CXCR1 (IL-8 receptor)‡ 0.130 0.106 0.227
CD54 (ICAM-1) −1.043 0.878 0.241
A17 (active FcγRII)‡ 0.127 0.051 0.016*
A27 (active FcγRII)‡ 0.102 0.045 0.028*
CD16− Eosinophils 0.680 0.695 0.334
Different multiple regression models with susceptibility to COPD (y/n) as
predictor value and change in expression of neutrophil markers (CD181/
CXCR1, CD54, A17 or A27) or % eosinophils after smoking (Tafter-Tbefore) as
dependent variable. B = regression coefficient. *Significant (p < 0.05). †all
models were adjusted for expression of marker at baseline, age and current
smoking n/y. ‡Data were log-transformed.
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primed neutrophils can be recognized by MoPhab anti-
bodies A17 and A27 since they bind FcγRII (CD32) only
in the context of primed cells and exquisitely capable to
detect primed cells in the circulation [10,13]. We found
that acute smoking significantly increased median A17
and A27 expression only in the group of young susceptible
subjects (Table 2, Figure 2). This effect was further con-
firmed by regression analyses, showing that this increase
was independently of age, smoking status and marker ex-
pression at baseline. In contrast, receptors involved in ad-
hesion and migration tended to decrease after smoking,
which was significant for ICAM-1 and CD182/CXCR2
markers in susceptible subjects and for CD181/CXCR1
and CD182/CXCR2 in non-susceptible subjects. Taken
together these data suggest that circulating neutrophils
become more activated immediately after smoking, and
particularly so in young susceptible subjects.
The underlying mechanisms are complex. Some in vitro
studies have shown that circulating neutrophils of smokers
are pre-activated or primed compared with never-smokersTable 6 Association of change in expression of neutrophil
activation markers and susceptibility with change in
number of bronchial NP57+ neutrophils in bronchial
biopsies
Outcome variable: change in number of bronchial NP57+ neutrophils
with smoking
n = 39, R2 = 0.620 β p-value
Change in CD54 expression (Tafter-Tbefore) 0.271 0.044*
NP57 expression at baseline −0.597 <0.001*
Susceptibility, n/y 0.386 0.013*
Current smoking, n/y 0.309 0.037*
Multiple regression model with susceptibility to COPD (y/n) as predictor value
and change in expression of neutrophil count in bronchial biopsies after
smoking (Tafter-Tbefore) as dependent variable. Β = standardized regression
coefficient. *Significant (p < 0.05).and have a higher capacity to migrate towards chemotactic
stimuli, or are more responsive to activating agents
[14,15]. We did not investigate chemotactic characteris-
tics of neutrophils, however, our data are pointing at a
mechanism by which neutrophils are more easily primed
in young susceptible individuals. This may contribute to a
higher influx of neutrophils into the airways, leading to
more intense inflammation and tissue damage. The trend
we found in reduced expression of ICAM-1 in young sus-
ceptible individuals supports this hypothesis. Neutrophils
with upregulated expression of adhesion molecules may
already have left the circulation infiltrating the lung tissue.
This concept has also been proposed for eosinophils in
allergic asthma by Johansson et al [16]. Interestingly,
we demonstrated that a higher increase of ICAM-1 ex-
pression on circulating neutrophils upon smoking was
associated with a higher increase of bronchial biopsy
neutrophils. In the same model, being susceptible to
develop COPD and current smoking were independent
predictors of neutrophil influx after smoking, indicating
that the influx of cells is higher in susceptible individ-
uals who smoke. However, no significant associations
were found between bronchial cell counts and the other
neutrophil activation markers. This lack in association
may be due to the fact that blood and bronchial biopsies
were collected at different time points. Nevertheless, it is
encouraging that our methods identified subtle alterations
in the activation state of circulating neutrophils associated
with changes in neutrophil numbers in the airways.
Blood eosinophil numbers decreased after smoking
both in young susceptible and non-susceptible subjects,
a finding in accordance with our previous study on
acute smoking effects in intermittent smokers [17]. An-
other study in four young healthy women demonstrated
a decreased number of eosinophils two hours after
smoking of 12 cigarettes [18]. Interestingly, eosinophil
numbers also significantly decreased after smoking in
COPD patients and healthy controls. The underlying
mechanism is yet to be defined, but a similar situation is
found upon systemic LPS challenge in man [19]. Appar-
ently, eosinophil homing signals are generated by innate
immune signals such as DAMPs (acute smoking) and
PAMPs (LPS). Our study did not show associations be-
tween smoking-induced changes in eosinophil numbers
and cytokine concentrations in blood, suggesting that
remaining eosinophils were not responsive to the cyto-
kines with respect to homing of the cells. Another ex-
planation might be that eosinophils migrated from the
circulation into the lung tissue. However, we did not
find an associated rise in eosinophil numbers in bron-
chial biopsies after smoking. A final explanation is that
toxic substances in cigarette smoke cause apoptosis
[20], a phenomenon we did not investigate specifically.
Interestingly, susceptible subjects had a deeper fall in
Figure 4 Association between change in expression of neutrophil activation markers and change in number of bronchial NP57+
neutrophils in bronchial biopsies after smoking. Values are expressed as change in median fluorescence intensity (MFI) (Tbefore – Tafter), two
hours after smoking.
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young and old population, although this finding did not
remain significant in multiple regression analysis. Ap-
parently, the eosinophilic response to cigarette smoke is
not contributing to susceptibility, in contrast to the neu-
trophilic response.
Next we investigated whether the differences in re-
sponses to cigarette smoke between young susceptible
and non-susceptible subjects were also present between
COPD patients and healthy controls. Here we found no
differences in expression of neutrophil activation markers
in peripheral blood after smoking, which may be due to
the fact that they were older and had more pack-years.
It is known that age and prolonged smoking increases
systemic inflammation [21]. Further, several studies have
demonstrated that neutrophils are more activated in COPD
patients [22], and this may have obscured a relatively subtle
response on recent smoking exposure. However, basal
levels of expression markers in both our old groups did
not differ, thus a different explanation is required. There,
we postulate that the inflammatory response to cigarette
smoking after long-term smoking has faded out or has
been switched into a more persistent inflammatory re-
sponse, minimizing the ability to detect subtle changes in
neutrophil activation.
Smoking of three cigarettes did not affect inflammatory
cell counts in bronchial biopsies 24 hours later. This con-
trasts with findings in animal models, where acute smok-
ing results in an influx of inflammatory cells in lung tissue
6-24 hours later [23-25]. The time point of 24 hours after
smoking was chosen based on animal studies given the
lack of data in men [2,7]. It may well be that the response
to cigarette smoking in human occurs early after smoking,
or that animals were exposed to relatively much higher
levels of cigarette smoke. Smoking in human has been shownto increase neutrophils in sputum [17], bronchoalveolar
lavage fluid (BALF) [26] and lung tissue using nuclear
imaging techniques [27]. Possibly, the main effects of
smoking do not take place in the large airways, but at
other lung regions like peripheral airways and lung par-
enchyma. Clearly, our negative biopsy findings can be
explained in a number of ways: collecting biopsies too
late after smoking, smoking of too few cigarettes, or in-
vestigating the wrong lung compartment. Future human
studies must take these considerations into account.
The strengths of our study are that we investigated
young individuals with normal lung function who are ei-
ther susceptible or not susceptible to develop COPD and
we used a disease-specific challenge to find biomarkers of
COPD susceptibility. There are some limitations as well.
First, we defined COPD susceptibility on familial history
of COPD only; no lung function measurements were
performed to verify COPD in family members. However,
family history of COPD is a strong risk factor of COPD
[5] and we maintained a strict inclusion algorithm [7].
Second, we used exhaled CO to verify smoking abstin-
ence before the acute smoking procedure, yet this is
only reliable within 6 hours of smoking cessation. Third,
the young susceptible group smoked a higher number of
pack-years compared with the susceptible group.
Fourth, the number of participants was relatively low,
especially in the young susceptible and the COPD
group. Additionally, we lost some data because 21% of
the subjects did not complete the two bronchoscopies.
However, our significant findings are relevant as they
were found in spite of the low sample size of this study.
In conclusion, we found that COPD susceptibility at
young age associates with an increased activation of per-
ipheral neutrophils after cigarette smoking. This increased
innate immune response was not found at old age, likely
Hoonhorst et al. Respiratory Research 2014, 15:121 Page 9 of 10
http://respiratory-research.com/content/15/1/121because the inflammatory response to cigarette smoking
has faded out or has been switched into a more persistent
inflammatory response as a result of long-term smoking
or aging. Our data emphasizes that systemic inflammation
contributes likely to the early induction phase of COPD.
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Abbreviations
COPD: Chronic obstructive pulmonary disease; FEV1: Forced expiratory
volume in one second; FVC: Forced vital capacity; CO: Carbon monoxide;
MEF: Maximal expiratory flow; MFI: Median fluorescence intensity;
RV: Residual volume; TLC: Total Lung capacity; TLCO: Transfer coefficient for
carbon monoxide; FRC: Functional residual capacity.
Competing interests
This research was done in the framework of the Top Institute Pharma project
T1-108 with partners University Medical Center Groningen (UMCG), University
of Groningen (RUG), GRIAC research institute Groningen, University Medical
Center Utrecht (UMCU), Nycomed BV, GlaxoSmithKline, and Foundation TI Pharma.
SH, LK, ALTL, HMB, and AO declare that they have no competing interests.
The university of Groningen, received fees for consultancies of WT from
Pzizer, GlaxoSmithKline, Chiesi, Roche Diagnostics/Ventana, and Dutch
Asthma Fund. JWL received consultancies from GlaxoSmithKline and Chiesi.
The University of Groningen, received fees for consultancies of DP from
AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Takeda,
Nycomed, and TEVA, and grants from AstraZeneca and Chiesi. NTH received
grants from GlaxoSmithKline, Boehringer Ingelheim, Nycomed, and Chiesi.
Authors’ contributions
SH: Contributed to data collection, data analysis, interpretation of data,
writing and editing of the manuscript. WT: Contributed to the study concept
and design, data analysis, interpretation of data, writing and editing of the
manuscript. LK: Contributed to the study concept and design, interpretation
of data, writing and editing of the manuscript. ALTL: Contributed to
interpretation of data, writing and editing of the manuscript. JWL:
Contributed to the study concept and design, interpretation of data, writing
and editing of the manuscript. HMB: Contributed to the data analysis,
interpretation of data, writing and editing of the manuscript. AO:
Contributed to the interpretation of data, writing and editing of the
manuscript. DP: Contributed to the study concept and design, data analysis,
interpretation of data, writing and editing of the manuscript. NH:
Contributed to the study concept and design, data analysis, interpretation of
data, writing and editing of the manuscript. All authors read and approved
the final manuscript.
Acknowledgements
The authors thank all participants for their cooperation in the study;
Monique Lodewijk, Judith van der Leij and Theo Bijma for the processing of
bronchial biopsies and peripheral blood; all partners from the Top Institute
Pharma project T1-108: Foundation TI Pharma, Nycomed BV, GlaxoSmithKline,
University Medical Center Groningen, University of Groningen (RUG).
Author details
1Department of Pulmonary Diseases, University of Groningen, University
Medical Center Groningen, Groningen, The Netherlands. 2GRIAC research
institute, University of Groningen, University Medical Center Groningen,
Groningen, The Netherlands. 3Department of Pathology, University of
Groningen, University Medical Center Groningen, Groningen, The
Netherlands. 4Department of Respiratory Medicine, University Medical Center
Utrecht, Utrecht, The Netherlands. 5Department of Epidemiology, University
of Groningen, University Medical Center Groningen, Groningen, The
Netherlands. 6Lab of Allergy and Pulmonary Diseases, University of
Groningen, University Medical Center Groningen, Groningen, The
Netherlands.Received: 25 June 2014 Accepted: 30 September 2014
References
1. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ,
Fabbri LM, Martinez FJ, Nishimura M, Stockley RA, Sin DD, Rodriguez-Roisin R:
Global strategy for the diagnosis, management, and prevention of chronic
obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit
Care Med 2013, 187(4):347–365.
2. van der Vaart H, Postma DS, Timens W, ten Hacken NH: Acute effects of
cigarette smoke on inflammation and oxidative stress: a review. Thorax
2004, 59(8):713–721.
3. Silverman EK, Chapman HA, Drazen JM, Weiss ST, Rosner B, Campbell EJ,
O'DONNELL WJ, Reilly JJ, Ginns L, Mentzer S, Wain J, Speizer FE: Genetic
epidemiology of severe, early-onset chronic obstructive pulmonary
disease. Risk to relatives for airflow obstruction and chronic bronchitis.
Am J Respir Crit Care Med 1998, 157(6 Pt 1):1770–1778.
4. McCloskey SC, Patel BD, Hinchliffe SJ, Reid ED, Wareham NJ, Lomas DA:
Siblings of patients with severe chronic obstructive pulmonary disease
have a significant risk of airflow obstruction. Am J Respir Crit Care Med
2001, 164(8 Pt 1):1419–1424.
5. Hersh CP, Hokanson JE, Lynch DA, Washko GR, Make BJ, Crapo JD,
Silverman EK, COPDGene Investigators: Family history is a risk factor for
COPD. Chest 2011, 140(2):343–350.
6. Patel BD, Coxson HO, Pillai SG, Agusti AG, Calverley PM, Donner CF, Make BJ,
Muller NL, Rennard SI, Vestbo J, Wouters EF, Hiorns MP, Nakano Y, Camp PG,
Nasute Fauerbach PV, Screaton NJ, Campbell EJ, Anderson WH, Pare PD, Levy
RD, Lake SL, Silverman EK, Lomas DA, International COPD Genetics Network:
Airway wall thickening and emphysema show independent familial
aggregation in chronic obstructive pulmonary disease. Am J Respir Crit Care
Med 2008, 178(5):500–505.
7. Lo Tam Loi AT, Hoonhorst SJ, Franciosi L, Bischoff R, Hoffmann RF, Heijink I,
van Oosterhout AJ, Boezen HM, Timens W, Postma DS, Lammers JW,
Koenderman L, Ten Hacken NH: Acute and chronic inflammatory responses
induced by smoking in individuals susceptible and non-susceptible to
development of COPD: from specific disease phenotyping towards novel
therapy. Protocol of a cross-sectional study. BMJ Open 2013, 3(2).
doi:10.1136/bmjopen-2012-002178. Print 2013.
8. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R,
Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC,
MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G,
Wanger J, ATS/ERS Task Force: Standardisation of spirometry. Eur Respir J
2005, 26(2):319–338.
9. Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, Casaburi R,
Crapo R, Enright P, van der Grinten CP, Gustafsson P, Hankinson J, Jensen R,
Johnson D, Macintyre N, McKay R, Miller MR, Navajas D, Pellegrino R, Viegi G:
Standardisation of the measurement of lung volumes. Eur Respir J 2005,
26(3):511–522.
10. Koenderman L, Kanters D, Maesen B, Raaijmakers J, Lammers JW, de Kruif J,
Logtenberg T: Monitoring of neutrophil priming in whole blood by
antibodies isolated from a synthetic phage antibody library. J Leukoc Biol
2000, 68(1):58–64.
11. Kato T, Kitagawa S: Regulation of neutrophil functions by
proinflammatory cytokines. Int J Hematol 2006, 84(3):205–209.
12. Hyun YM, Lefort CT, Kim M: Leukocyte integrins and their ligand
interactions. Immunol Res 2009, 45(2–3):195–208.
13. Oudijk EJ, Gerritsen WB, Nijhuis EH, Kanters D, Maesen BL, Lammers JW,
Koenderman L: Expression of priming-associated cellular markers on neutrophils
during an exacerbation of COPD. Respir Med 2006, 100(10):1791–1799.
14. Blidberg K, Palmberg L, Dahlen B, Lantz AS, Larsson K: Increased neutrophil
migration in smokers with or without chronic obstructive pulmonary
disease. Respirology 2012, 17(5):854–860.
15. Koethe SM, Kuhnmuench JR, Becker CG: Neutrophil priming by cigarette
smoke condensate and a tobacco anti-idiotypic antibody. Am J Pathol
2000, 157(5):1735–1743.
16. Johansson MW: Activation states of blood eosinophils in asthma. Clin Exp
Allergy 2014, 44(4):482–498.
17. van der Vaart H, Postma DS, Timens W, Hylkema MN, Willemse BW, Boezen HM,
Vonk JM, de Reus DM, Kauffman HF, ten Hacken NH: Acute effects of
cigarette smoking on inflammation in healthy intermittent smokers.
Respir Res 2005, 6:22.
Hoonhorst et al. Respiratory Research 2014, 15:121 Page 10 of 10
http://respiratory-research.com/content/15/1/12118. Winkel P, Statland BE: The acute effect of cigarette smoking on the
concentrations of blood leukocyte types in healthy young women. Am J
Clin Pathol 1981, 75(6):781–785.
19. Kamp VM, Leentjens J, Pillay J, Langereis JD, de Kleijn S, Kox M, Netea MG,
Pickkers P, Koenderman L: Modulation of granulocyte kinetics by
GM-CSF/IFN-gamma in a human LPS rechallenge model. J Leukoc
Biol 2013, 94(3):513–520.
20. Aoshiba K, Tamaoki J, Nagai A: Acute cigarette smoke exposure induces
apoptosis of alveolar macrophages. Am J Physiol Lung Cell Mol Physiol
2001, 281(6):L1392–L1401.
21. Provinciali M, Cardelli M, Marchegiani F: Inflammation, chronic obstructive
pulmonary disease and aging. Curr Opin Pulm Med 2011,
17(Suppl 1):S3–S10.
22. Oudijk EJ, Lammers JW, Koenderman L: Systemic inflammation in chronic
obstructive pulmonary disease. Eur Respir J Suppl 2003, 46:5s–13s.
23. Vitalis TZ, Kern I, Croome A, Behzad H, Hayashi S, Hogg JC: The effect of
latent adenovirus 5 infection on cigarette smoke-induced lung
inflammation. Eur Respir J 1998, 11(3):664–669.
24. Hulbert WC, Walker DC, Jackson A, Hogg JC: Airway permeability to
horseradish peroxidase in guinea pigs: the repair phase after injury by
cigarette smoke. Am Rev Respir Dis 1981, 123(3):320–326.
25. Kilburn KH, McKenzie W: Leukocyte recruitment to airways by cigarette
smoke and particle phase in contrast to cytotoxicity of vapor. Science
1975, 189(4203):634–637.
26. Morrison D, Strieter RM, Donnelly SC, Burdick MD, Kunkel SL, MacNee W:
Neutrophil chemokines in bronchoalveolar lavage fluid and
leukocyte-conditioned medium from nonsmokers and smokers. Eur
Respir J 1998, 12(5):1067–1072.
27. MacNee W, Wiggs B, Belzberg AS, Hogg JC: The effect of cigarette
smoking on neutrophil kinetics in human lungs. N Engl J Med 1989,
321(14):924–928.
doi:10.1186/s12931-014-0121-2
Cite this article as: Hoonhorst et al.: Increased activation of blood
neutrophils after cigarette smoking in young individuals susceptible to
COPD. Respiratory Research 2014 15:121.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
